• Risk Stratification and Identification of Immunogenetic and Microbial Markers of Complicated Disease Course in Pediatric Crohn’s Disease (CD) sponsored by the CCFA (patients in follow-up, no longer enrolling)
• Causes and consequences of neutrophil dysfunction in early onset Crohn’s Disease (CD) sponsored by the NIDDK (patients in follow-up)
• Risk Stratification and Partners Kids and Teens Study of Linkage and Internet Based Cohort for Ulcerative Colitis (UC) or Crohn’s Disease (CD) sponsored by the CCFA (patients in follow-up, no longer enrolling)
• A Phase 3, Double-Blind, Placebo Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Adult Patients with Moderate to Severe Active Ulcerative Colitis who are Refractory to or Intolerant of TNF Inhibitors sponsored by Genentech (now enrolling)
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction and Maintenance Treatment for Patients with Moderately to Severely Active Crohn's Disease sponsored by Genentech (now enrolling)
• A Phase 3, Double-Blind, Placebo Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Adult Patients with Moderate to Severe Active Ulcerative Colitis who are Naïve to TNF Inhibitors sponsored by Genentech (now enrolling)
• A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of Humira® (Adalimumab) in Pediatric Patients with Moderately to Severely Active Crohn's Disease (CD) – CAPE sponsored by AbbVie (now enrolling)
• A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients with Inflammatory Bowel Disease sponsored by Janssen Pharmaceuticals (now enrolling)
• Predicting Response to Standardized Pediatric Colitis Therapy: The PROTECT Study for Children with Newly Diagnosed Ulcerative Colitis (UC) sponsored by the NIH (patients in follow-up, no longer enrolling)
• A Phase 1b Open-Label Trial to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a human anti-TNFα Antibody, In Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis (UC) sponsored by Janssen Pharmaceuticals (patients in follow-up, no longer enrolling)
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Ulcerative Colitis sponsored by AbbVie (now enrolling)
• Quality Improvement Initiative called Improve Care Now (ICN) in Inflammatory Bowel Disease (IBD) sponsored by UCSF Medical Center (now enrolling)
• A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients with Inflammatory Bowel Disease (IBD) sponsored by Janssen Pharmaceuticals (patients in follow-up, enrolling UC and IC patients)
• Telehealth Enhancement of Adherence to Medication (TEAM study) in Pediatric Inflammatory Bowel Disease (IBD) in collaboration with CCHMC sponsored by the NIH (patients in follow-up, no longer enrolling)
• The Orchestra Pilot Project: Enhancing Patient-Provider Partnerships Using The Orchestra Platform (now enrolling)
• Viral Community in Pediatric Inflammatory Bowel Disease (IBD) Patients (study completed)
• The S1P Study: A Study of Obesity, Genetics and Cancer in Pediatric Inflammatory Bowel Disease (IBD) in patients aged 1-25 undergoing a colonoscopy (now enrolling)
• INSPPIRE is a multi-center, prospective registry of children with acute recurrent and chronic pancreatitis. The goal of the study is to understand the causes and progression of pancreatitis in children, and to create a group in which new treatments can be developed to reduce pain, hospitalizations, and diabetes and to improve quality of life (Enrolling)
• A Multicentre, Randomized, Placebo-controlled, Double-blind Study of the Efficacy, Safety, and Pharmacokinetics of Lubiprostone in Pediatric Subjects Aged ≥ 6 Years to < 18 Years with Functional Constipation (Phase 3 Trial) as well as a Multicentre, Long-Term Safety, Efficacy, and Pharmacokinetics Study of Lubiprostone in Pediatric Subjects Aged ≥ 6 Years to < 18 Years with Functional Constipation sponsored by Sucampo AG (patient in follow-up)
• A prospective, multi-center registry for pediatric patients with short bowel syndrome. The purpose of this registry is to evaluate long-term clinical outcomes in children with SBS, both those treated with Teduglutide and those not treated with Teduglutide (TED-R13-002) sponsored by Shire (Enrolling soon)
• A 24-week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age with Short Bowel Syndrome who are Dependent on Parenteral Support (TED-C14-006) sponsored by Shire (Enrolling soon)
For more information about the latest research studies at UCSF, please contact Liz Garnett at (415) 514-4423 or via email [email protected]